Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (less than 120 minutes) invasive management (percutaneous coronary intervention [PCI]) is not indicated. Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care. AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | fondaparinux (Arixtra®) | |
| Formulation | solution for injection | |
| Reference number | 148 | |
| Indication | Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (<120 minutes) invasive management (percutaneous coronary intervention [PCI]) is not indicated |
|
| Company | GlaxoSmithKline | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0608 | |
| NMG meeting date | 13/03/2008 | |
| AWMSG meeting date | 16/04/2008 | |
| Ratification by Welsh Government | 20/05/2008 | |
| Date of issue | 22/05/2008 | |